4 different doctors' views on Aromatase Inhibitors for LCIS

Thought I'd pass on these 4 views that were shared with me over the course of a couple of months.

#1 Oncologist in USA: Advocated AIs and emphasized that they decrease breast cancer risk by over 50% for those with LCIS. Exemastane is first choice. Next choice, when Exemastane was not tolerated was Letrozole.

#2 Oncologist in USA: None of the three Aromatase Inibitors (Exemastane/Aromasin, Letrozole/Femara, Armidex/Anastrozole) are FDA approved for reduction of breast cancer in high risk patients. Both Tamoxifen and Raloxifene/Evista are FDA approved. Therefore the AIs would not be prescribed because there are no studies yet that show their effect in women who are at high risk, even though these are effective for women with breast cancer. Instead, Tomxifen or Raloxifene/Evista are good chemoprevention choices for LCIS.

#3 Cardiologist in USA: "I would not suggest AIs for benign proliferate breast disease. Do surveillance instead."

#4 Radiologist in UK, who is an acquaintance: AIs are too extreme for LCIS.